TY  - GEN
AU  - Campbell,Aideen M
AU  - Morris,Melanie
AU  - Gallagher,Rebecca
AU  - Boyd,Ruth
AU  - Carson,Hazel
AU  - Harkin,D Paul
AU  - Wielogorska,Ewa
AU  - Elliott,Christopher
AU  - Savage,Kienan I
AU  - McIntosh,Stuart A
TI  - Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
SN  - 2044-6055
PY  - 2019///1029
KW  - Adult
KW  - Anastrozole
KW  - therapeutic use
KW  - Antineoplastic Agents, Hormonal
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Chemoprevention
KW  - methods
KW  - Cross-Over Studies
KW  - Disease-Free Survival
KW  - Feasibility Studies
KW  - Female
KW  - Genetic Predisposition to Disease
KW  - epidemiology
KW  - Goserelin
KW  - Heterozygote
KW  - Humans
KW  - Mutation
KW  - Northern Ireland
KW  - Patient Acceptance of Health Care
KW  - statistics & numerical data
KW  - Patient Selection
KW  - Premenopause
KW  - physiology
KW  - Prognosis
KW  - Risk Assessment
KW  - Survival Rate
KW  - Tamoxifen
KW  - Treatment Outcome
KW  - Ubiquitin-Protein Ligases
KW  - genetics
N1  - Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1136/bmjopen-2018-023115
ER  -